Results 11 to 20 of about 208,148 (266)

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice [PDF]

Leukemia, 2011
Although BCR-ABL+ stem cells in chronic myeloid leukemia (CML) resist elimination by targeted pharmacotherapy in most patients, immunological graft-versus-leukemia effects can cure the disease. Besides cytotoxic T cells, natural killer (NK) cells may have a role in immune control of CML.
Holden T. Maecker, Mirle Schemionek, Linda Kerstiens, Heribert Juergens, Claudia Rossig, Peter P. Lee, Wolfgang E. Berdel, Bianca Altvater, C I-U Chen, Steffen Koschmieder, Joachim Gerss, Sibylle Pscherer   +11 more
openaire   +3 more sources

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib [PDF]

Blood Cancer Journal, 2015
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL -positive chronic myelogenous leukemia treated with ruxolitinib and ...
Amy Zhou, Elizabeth K. Engle, Eric M. Knoche, Daniel A.C. Fisher, Stephen T. Oh   +4 more
openaire   +3 more sources

Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells [PDF]

Cell Research, 2008
This study examined the signaling events induced by shikonin that lead to the induction of apoptosis in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells (e.g., K562, LAMA84). Treatment of K562 cells with shikonin (e.g., 0.5 muM) resulted in profound induction of apoptosis accompanied by rapid generation of reactive oxygen species (ROS ...
Wen Hua Li, Xin Mao, Wenxin Li, Chun Rong Yu   +3 more
openaire   +4 more sources

Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia

Pharmacological Research, 2022
Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that accounts for about 15% of all cases of leukemia. This disorder results from the formation of the Philadelphia chromosome that involves a reciprocal translocation that produces a lengthened chromosome 9 and shortened chromosome 22 - the Philadelphia chromosome.
R. Roskoski
openaire   +3 more sources

T-Lymphoblastic Leukemia With t(9;22): Blast Phase of Chronic Myelogenous Leukemia or BCR-ABL- Positive T-Acute Lymphoblastic Leukemia? [PDF]

American Journal of Clinical Pathology, 2012
T-acute lymphoblastic leukemia/lymphoma (T-ALL) as chronic myelogenous leukemia blast phase (CML-BP) is rare. BCR-ABL–positive T-ALL is extremely rare. In patients without previous/concurrent history of CML, it is difficult to differentiate these 2 entities. Herein we report 3 cases of T-ALL with t(9;22) and review the literature.
Jie Xu, Shaoying Li
openaire   +3 more sources

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia [PDF]

Blood Cancer Journal, 2014
Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation.
Dong-Wook Kim, Giovanni Martinelli, Arnon Nagler, J. L. Jimenez, Francis J. Giles, A. Haregewoin, Timothy P. Hughes, P. Watson, Mahon Fx, John F. Seymour, Philippe Rousselot, Cristina Papayannidis, Inge Høgh Dufva, Jason Clark, Jason Clark, Eric J. Rubin, Jorge E. Cortes   +16 more
openaire   +6 more sources

Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients [PDF]

Blood, 1993
Abstract We report here the results of polymerase chain reaction (PCR) for bcr- abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 ...
Yasuo Morishima, Kunihiko Takeyama, Shinobu Tsuzuki, Hiroshi Saito, Yoshihisa Morishita, Mitsune Tanimoto, Yoshihisa Kodera, Kohei Kawashima, Koichi Miyamura, Tahara T   +9 more
semanticscholar   +6 more sources

Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia [PDF]

Leukemia, 2001
To investigate the mechanisms behind the leukemic expansion of BCR/ABL-positive chronic myelogenous leukemia (CML), we examined the cell cycle status of hematopoietic progenitor cells from peripheral blood (PB) and bone marrow (BM) of 37 patients with newly diagnosed BCR/ABL-positive CML.
Alwin Krämer, Harald Löffler, Ruediger Hehlmann, Andreas Hochhaus, Jörg Bergmann   +4 more
openaire   +4 more sources

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells [PDF]

Leukemia, 2001
The ABL-specific tyrosine kinase inhibitor STI571 (formerly CGP57148B) induced cytogenetic remissions in 33% of chronic myelogenous leukemia (CML) patients in a phase I trial (Druker et al 1999). Combination therapy may increase this proportion. We tested whether combinations of STI571 and cytarabine or other chemotherapeutic agents such as hydroxyurea,
W. J. Zeller, J Topaly, Stefan Fruehauf
openaire   +4 more sources

Is There an Entity of Chemically Induced BCR-ABL–Positive Chronic Myelogenous Leukemia?

The Oncologist, 2008
Abstract Learning Objectives After completing this course, the reader will be able to: Distinguish the exogenous causes of acute and chronic myelogenous leukemia.Discuss the evidence establishing the exogenous causes of secondary leukemia.Describe the relationship of radiation and chemical exposure to
M. Lichtman
openaire   +4 more sources